TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03259516
Drug: Melphalan
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2 mg per os daily during the whole course of treatment
Study: NCT01471691
Drug: ranibizumab 0.5mg
Normalized name: RANIBIZUMAB 0.5MG/0.05ML INJ,OPH
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Standard dose
Study: NCT01471691
Drug: ranibizumab 1.0mg
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: High dose
Study: NCT01318967
Drug: Furosemide
Normalized name: Furosemide
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Renal blood flow is measured after the administration of 20 mg of furosemide during MRI scan only.
Study: NCT02652091
Drug: Interferon beta-1b (Betaseron, BAY86-5046)
Normalized name: Interferon Beta-1B
DrugBank: Interferon beta-1b (DB00068)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Applied via the BETACONNECT device. Dose as prescribed by physician.
Study: NCT02319564
Drug: Beclomethasone
Normalized name: Beclomethasone
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04559126
Drug: EDP-297
Normalized name: INDIGOFERA TINCTORIA LEAF 0.999 in 100 g TOPICAL POWDER [EDP INDIGO]
DrugBank: Indigofera tinctoria leaf (DB14314)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EDP-297 Oral solution
Study: NCT01066767
Drug: Fexofenadine
Normalized name: Fexofenadine
DrugBank: Fexofenadine (DB00950)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fexofenadine Hydrochloride 180 mg Tablets
Study: NCT04910698
Drug: Antibiotic
Normalized name: Antibiotics
DrugBank: Gramicidin D (DB00027)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic duration of treatment defined if the patient belonged to long course or short course group.
Study: NCT02551536
Drug: Montelukast
Normalized name: Montelukast
DrugBank: Montelukast (DB00471)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02551536
Drug: Fexofenadine
Normalized name: Fexofenadine
DrugBank: Fexofenadine (DB00950)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: group B received FDC tablet of montelukast 10mg and fexofenadine 120 mg O.D
Study: NCT01762592
Drug: Iodine (124I) Girentuximab
Normalized name: IODINE (124I) GIRENTUXIMAB
DrugBank: Girentuximab I-124 (DB15025)
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v.
Study: NCT02721290
Drug: Ropivacaine 0.5%
Normalized name: ROPivacaine 0.5% injectable solution
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ropivacaine 0.5% (20cc total) will be injected for the performance of the block in the two arms of the study.
Study: NCT00000244
Drug: Dynorphin 1 - 13
DrugBank: Dynorphin (DB16146)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00060567
Drug: E7070 + irinotecan combination
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Escalating doses starting from 125 mg/m2 irinotecan plus 250 mg/m2 E7070 combination.
Study: NCT00060567
Drug: Irinotecan + E7070 combination
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Escalating doses starting from 100 mg/m2 irinotecan plus 400 mg/m2 E7070 combination.
Study: NCT00236574
Drug: Galantamine hydrobromide
Normalized name: Galantamine Hydrobromide
DrugBank: Galantamine (DB00674)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00006017
Drug: becatecarin
Normalized name: Becatecarin
DrugBank: Becatecarin (DB06362)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arm I: Patients receive rebeccamycin analogue IV over 1 hour on day 1. Arm II: Patients receive rebeccamycin analogue IV over 1 hour on days 1-5. Treatment for both arms repeats every 3 weeks for 6-8 courses in the absence of disease progression or unacceptable toxicity.
Study: NCT03443141
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The applied dressing will be embebbed in Vitamin E
Study: NCT02017197
Drug: generic warfarin #1
DrugBank: Warfarin (DB00682)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Generic warfarin sodium tablets, manufacturer (União Química Farmacêutica Nacional S/A, Brazil), by mouth; dose adjusted according to INR and medical judgement.
Study: NCT02017197
Drug: generic warfarin #2
DrugBank: Warfarin (DB00682)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Generic warfarin sodium tablets, manufacturer (Laboratório Teuto Brasileiro S/A, Brazil), by mouth; dose adjusted according to INR and medical judgement.
Study: NCT03489863
Drug: Prasugrel
Normalized name: Prasugrel
DrugBank: Prasugrel (DB06209)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Maintenance dose will be maintained for 10±3 days.
Study: NCT03489863
Drug: Ticagrelor
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Maintenance dose will be maintained for 10±3 days.
Study: NCT00979901
Drug: Comparator: montelukast
DrugBank: Montelukast (DB00471)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 mg montelukast tablet given once daily at bedtime for 2 weeks
Study: NCT00003572
Drug: mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00003572
Drug: tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03407027
Drug: Quadratus triamcinolone
Normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 40mg of triamcinolone and 10ml of levobupivacaine 0,25%.
Study: NCT03407027
Drug: Gluteus triamcinolone
Normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 40mg of triamcinolone and 10ml of levobupivacaine 0,25%.
Study: NCT00979901
Drug: Comparator: loratadine
DrugBank: Loratadine (DB00455)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 mg loratadine tablet given once daily at bedtime for 2 weeks
Study: NCT03407027
Drug: quadratus without triamcinolone.
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10ml of levobupivacaine 0,25%.
Study: NCT00979901
Drug: Comparator: montelukast/loratadine
DrugBank: Loratadine (DB00455)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: montelukast 10-mg/loratadine 10-mg combination tablet taken orally once daily at bedtime for 2 weeks
Study: NCT01702974
Drug: vitamin D (cholecalciferol) and PBA (sodium phenylbutyrate)
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose of interventions: 5,000 IU of vitamin D (cholecalciferol tablets) once daily and 500 mg PBA (sodium phenylbutyrate tablets) twice daily for 16 weeks.
Study: NCT03867214
Drug: Glutamine
Normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 g of tranexamic acid in 100 mL of normal saline intravenously approximately 15 minutes before incision
Study: NCT03647280
Drug: Epirubicin
Normalized name: Epirubicin
DrugBank: Epirubicin (DB00445)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tailored neoadjuvant chemotherapy with 4 cycles of PE(weekly Abraxane 125mg/m2, Q3week Epirubicin 100mg/m2, 21day/cycle) is planned for early breast cancer patients(stage of T2-4N0-3M0) who are eligible for primary systemic therapy.
Study: NCT01576887
Drug: Bardoxolone Methyl 20 mg
Normalized name: methylal
DrugBank: Bardoxolone methyl (DB05983)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral, once daily
Study: NCT01005251
Drug: lesogaberan (AZD3355)
Normalized name: Lesogaberan
DrugBank: Lesogaberan (DB11920)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg, oral, capsules, bid for 4 w
Study: NCT01005251
Drug: lesogaberan (AZD3355)
Normalized name: Lesogaberan
DrugBank: Lesogaberan (DB11920)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 mg, oral, capsules, bid for 4 w
Study: NCT01005251
Drug: lesogaberan (AZD3355)
Normalized name: Lesogaberan
DrugBank: Lesogaberan (DB11920)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 180 mg, oral, capsules, bid for 4 w
Study: NCT01005251
Drug: lesogaberan (AZD3355)
Normalized name: Lesogaberan
DrugBank: Lesogaberan (DB11920)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 240 mg, oral, capsules, bid for 4 w
Study: NCT00382668
Drug: Dasatinib
Normalized name: Dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tablets, Oral, 50 mg, once daily, for one day
Study: NCT03541668
Drug: Recombinant human urokinase
DrugBank: Urokinase (DB00013)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients receive rhPro-UK 35mg,15mg of which is given as a bolus within 3 minutes followed by dlivery of the remaining 20 mg as a constant infusion over a period of 30 minutes.
Study: NCT00382668
Drug: Dasatinib
Normalized name: Dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tablets, Oral, 20 mg, once daily for one day
Study: NCT00382668
Drug: Dasatinib
Normalized name: Dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tablets, Oral, 70 mg, once daily for one day
Study: NCT01531764
Drug: BIBW 2992 in combination with vinorelbine
DrugBank: Vinorelbine (DB00361)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive BIBW 2992 and vinorelbine chemotherapy. BIBW 2992: 40 mg oral (tablet) once daily Vinorelbine: 25 mg/m² on days 1 \& 8 in a 3-weekly course, intravenous, short infusion of about 10 minutes
Study: NCT04236440
Drug: BAY2586116 (A1)
Normalized name: Zygomycin A1
DrugBank: Paromomycin (DB01421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 160 μg BAY2586116 (nasal spray administration)
Study: NCT04236440
Drug: BAY2586116 (B2)
Normalized name: VITAMIN B2
DrugBank: Riboflavin (DB00140)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 80 μg BAY2586116 (nasal spray)
Study: NCT04236440
Drug: BAY2586116 (C)
Normalized name: Vitamin C
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 160 μg BAY2586116 (pharyngeal spray with direct endoscopic application via a nostril). It is the same procedure as described under part B3.
Study: NCT00536458
Drug: MINI CHEP
Normalized name: oxymetazoline hydrochloride Nasal Solution [Iliadin Mini]
DrugBank: Oxymetazoline (DB00935)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: chemotherapy minichep 6 courses
Study: NCT01804413
Drug: Pegvisomant
Normalized name: Pegvisomant
DrugBank: Pegvisomant (DB00082)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pegvisomant 1 mg/kg injection 3 days before the glucagon test.
Study: NCT01076270
Drug: plerixafor
Normalized name: Plerixafor
DrugBank: Plerixafor (DB06809)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given SC
Study: NCT02543801
Drug: Liposomal Bupivacaine
Normalized name: bupivacaine liposome
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Periarticular injection
Study: NCT02543801
Drug: Ropivacaine
Normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Periarticular injection
Study: NCT02543801
Drug: Bupivacaine
Normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Included as an element of the Liposomal bupivacaine intervention periarticular injection
Study: NCT02543801
Drug: Clonidine
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Included as an element of both interventions as a standard of care periarticular injection
Study: NCT02765854
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT02765854
Drug: Ixazomib
Normalized name: Ixazomib
DrugBank: Ixazomib (DB09570)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT02765854
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT03501381
Drug: Entinostat
Normalized name: entinostat
DrugBank: Entinostat (DB11841)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Entinostat should be taken 1-2 hours prior to the HD IL-2 infusion. Dose reductions for entinostat should be followed. Entinostat will continue after high dose IL-2 every 2 weeks
Study: NCT03501381
Drug: Interleukin-2
Normalized name: INTERLEUKIN-2
DrugBank: Human interleukin-2 (DB14865)
Approvals — FDA: no, EMA: no, PMDA: no
Description: In the event of clinical benefit after a course of HD IL-2 (stable disease or tumor shrinkage) patients will receive a second treatment course of HD IL-2 therapy. Patients with evidence of tumor shrinkage after the 2nd HD IL-2 treatment course may receive a 3rd treatment course of HD IL-2.
Study: NCT00923806
Drug: Aldesleukin
Normalized name: Aldesleukin
DrugBank: Aldesleukin (DB00041)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 720,000 IU/kg intravenous over 15 minutes every 8 hours for up to 5 days
Study: NCT03002675
Drug: Bydureon
Normalized name: Bydureon
DrugBank: Exenatide (DB01276)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: exenatide (Bydureon) 2mg s.c. 1x/wk
Study: NCT02499159
Drug: Liposomal Bupivicaine
Normalized name: bupivacaine liposome
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 266 mg, 20 mL total, diluted at surgeon's discretion, delivered by 22 gauge needle.
Study: NCT03296540
Drug: Prasugrel (Crushed tablets)
Normalized name: prasugrel Oral Tablet
DrugBank: Prasugrel (DB06209)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: loading dose of 6 crushed tablets 10mg Prasugrel
Study: NCT00937352
Drug: Bapineuzumab
Normalized name: Bapineuzumab
DrugBank: Bapineuzumab (DB11715)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg/kg, administered via IV (in the vein) infusion every 13 weeks for 4 years.~1.0 mg/kg, administered via IV (in the vein) infusion every 13 weeks for 4 years.
Study: NCT03525821
Drug: Ketamine Hydrochloride
Normalized name: Ketamine Hydrochloride
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intranasal use of ketamine 1mg/kg with nitrous oxide
Study: NCT03541668
Drug: Alteplase
Normalized name: Alteplase
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients receive rt-PA in a dose of 0.9mg per kilogram of body weight(maximum,90 mg),10 percent of which was given as a blous followed by delivery of the remaining 90 percent as a constant infusion over a period of 60 minutes.
Study: NCT00819091
Drug: BI 1356
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5mg orally (po) tablet qd
Study: NCT03296540
Drug: Prasugrel (Integral tablets)
Normalized name: prasugrel Oral Tablet
DrugBank: Prasugrel (DB06209)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: loading dose of 6 integral tablets of 10mg Prasugrel
Study: NCT00682760
Drug: Korean Botulinum toxin type A (KbtxA) and Botox injection
Normalized name: botulinum toxin type A Injection [Botox]
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Each vial of Botox and KbtxA contained 100 U of BTX-A in a sterile vacuum-derived form without preservatives. Each vial of KbtxA was identical to the placebo (Botox) vial, and all vials were reconstituted with 2.0 mL of 0.9% sterile nonpreserved saline solution to a final dilution of 5 U /0.1 mL. The dose of BTX-A per injection site was 2.5 U to 5 U, and the location, number of injection sites. Using a 30-gauge needle, injections were angled away from the center of lid to reduce the risk of spread into the levator muscle. Injection sites include the upper medial and lateral eyelid margins, lower lateral lid margins, and above the eyebrow.
Study: NCT01599793
Drug: cabozantinib
Normalized name: Cabozantinib
DrugBank: Cabozantinib (DB08875)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT02217514
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02217514
Drug: BI 44370 low dose
Normalized name: BI 44370 TA
DrugBank: BI 44370 TA (DB16037)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02217514
Drug: BI 44370 medium dose
Normalized name: BI 44370 TA
DrugBank: BI 44370 TA (DB16037)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02217514
Drug: BI 44370 high dose
Normalized name: BI 44370 TA
DrugBank: BI 44370 TA (DB16037)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03977792
Drug: Docosanol Cream 10%
DrugBank: Docosanol (DB00632)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Comparator product topically applied to infected area, 5 times a day, until complete healing of the infection.
Study: NCT00000266
Drug: Flupenthixol
Normalized name: flupenthixol
DrugBank: Flupentixol (DB00875)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02381470
Drug: Faropenem
Normalized name: Faropenem
DrugBank: Faropenem (DB12190)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Faropenem 600mg
Study: NCT02381470
Drug: Amoxicillin/clavulanic acid
DrugBank: Clavulanic acid (DB00766)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxicillin 500mg/ clavulanic acid 125mg
Study: NCT02381470
Drug: Cefadroxil
Normalized name: Cefadroxil
DrugBank: Cefadroxil (DB01140)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefadroxil 1g
Study: NCT02381470
Drug: Rifampicin
Normalized name: Rifampicin
DrugBank: Rifampin (DB01045)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rifampicin 10mg/kg
Study: NCT02808351
Drug: Berberine
Normalized name: berberine
DrugBank: Berberine (DB04115)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02097394
Drug: Bifidobacteri
Normalized name: BIFIDOBACTERIA
DrugBank: Bifidobacterium longum infantis (DB14222)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bifidobacteri (2 tablet, po, tid)
Study: NCT02097394
Drug: Combizym + Bifidobacteri
Normalized name: BIFIDOBACTERIUM
DrugBank: Bifidobacterium spp. (DB18530)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combizym( 1 tablet, po, tid) + Bifidobacteri (2 tablet, po, tid)
Study: NCT02369484
Drug: Afatinib
Normalized name: Afatinib
DrugBank: Afatinib (DB08916)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 40mg p.o./ day until documented progression or unacceptable toxicity
Study: NCT00329264
Drug: Quetiapine fumarate
Normalized name: Quetiapine Fumarate
DrugBank: Quetiapine (DB01224)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00642850
Drug: methoxy polyethylene glycol-epoetin beta [Mircera]
DrugBank: Methoxy polyethylene glycol-epoetin beta (DB09107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 120, 200 or 360 micrograms iv monthly (starting dose)
Study: NCT00162422
Drug: albuterol
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01162967
Drug: Benznidazole
Normalized name: benznidazole
DrugBank: Benznidazole (DB11989)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard dosage
Study: NCT01162967
Drug: Posaconazole
Normalized name: Posaconazole
DrugBank: Posaconazole (DB01263)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT01673308
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lenalidomide 10 mg orally on days 1 to 21 of a 28-day cycle for at least 4 cycles until intolerance or disease progression.
Study: NCT00141453
Drug: olmesartan medoxomil
Normalized name: Olmesartan Medoxomil
DrugBank: Olmesartan (DB00275)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablets 10, 20, or 40 mg
Study: NCT02252042
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 75 mg/m\^2 IV on Day 1 of each 3- week cycle
Study: NCT02818309
Drug: Lesogaberan
Normalized name: Lesogaberan
DrugBank: Lesogaberan (DB11920)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 mg bid
Study: NCT00071799
Drug: Azacitidine
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Azacitidine was injected subcutaneously (SC) at an initial dose of 75mg/m\^2/day for 7 days. The 7-day dosing was repeated every 28 days with dose adjustment based on predefined hematology and renal laboratory results. Number of cycles: Azacitidine treatment was to be continued until the end of the study unless treatment was discontinued due to unacceptable toxicity, relapse after complete or partial response, transformation to AML or disease progression.
Study: NCT02345174
Drug: 89Zr-GSK2849330
Normalized name: 89ZR-BEVACIZUMAB
DrugBank: Bevacizumab zirconium Zr-89 (DB14907)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 89Zr-GSK2849330 solution for intravenous administration diluted with GSK2849330 Solution for Infusion (unlabelled GSK2849330) with a target radioactivity of 37MBq and a total antibody concentration of 0.4 mg/mL or 1.2 mg/mL.
Study: NCT01432106
Drug: Aliskerin/Valsartan and Rampiril
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients will start on low dose Ramipril 10 mg or Valturna 150/160 at visit 2, and up-titrate to target dose of Ramipril 20 mg or Valturna 300/320 at visit 3. At visit 5, the addition of Hydrochlorothiazide (HCTZ) or amlodipine will be allowed to achieve the SBP target of \< 140 mmHg. High dose will then be maintained throughout the remainder of the study. In case of symptoms of low blood pressures, the study medication may be decreased to the low dose.~(However, all non-study medication will be manipulated, initially.)
Study: NCT03065816
Drug: Z0063
Normalized name: Zolpidem
DrugBank: Zolpidem (DB00425)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pharmaceutical form: chewable tablets Route of administration: oral
Study: NCT03065816
Drug: Gaviscon
Normalized name: Gaviscon
DrugBank: Aluminum hydroxide (DB06723)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: chewable tablets Route of administration: oral
Study: NCT02656017
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monitoring of tolerability and symptoms.
Study: NCT01308541
Drug: arm 1
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bolus Dose: two bolus doses of 15.0 mg/kg (first dose) and 8.0 mg/kg (second dose), 40 minutes apart.~Continuous Infusion Dose: Total dose of 42.0 mg/kg administered over 3 hours at an infusion rate of 0.40 mg/kg/min for 1 hour, followed by 0.20 mg/kg/min for 1 hour, followed by 0.10 mg/kg/min for 1 hour.
Study: NCT01308541
Drug: LUSEDRA
Normalized name: Lusedra
DrugBank: Fospropofol (DB06716)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mode of administration: intravenous (IV).Continuous Infusion Dose: Total dose of 42.0 mg/kg administered over 3 hours at an infusion rate of 0.40 mg/kg/min for 1 hour, followed by 0.20 mg/kg/min for 1 hour, followed by 0.10 mg/kg/min for 1 hour.
Study: NCT01308541
Drug: Propofol (arm 3)
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mode of administration: intravenous (IV). A loading dose administered at a constant infusion rate of 0.20 mg/kg/min (0.50 mL/kg/min) for 10 minutes, followed by a constant-rate 2-hour infusion at 0.10 mg/kg/min; total dose infused over 130 minutes is 14.0 mg/kg.